HOME >> BIOLOGY >> NEWS
Growth hormone, obesity can trigger sleep apnea in some kids

Growth hormone helps hundreds of children with a rare disorder that causes them to gorge on food, but for some, starting treatment can worsen a dangerous nighttime breathing problem, University of Florida researchers have found.

Sleep apnea disrupts breathing during sleep and is common among morbidly obese children, including those with Prader-Willi syndrome, a disease that compels them to eat nonstop. Researchers say that uncovering how to treat obesity and related problems in children genetically wired to be overweight could help them better battle childhood obesity in general.

Growth hormone has shown to be one of the most effective ways to treat children and adults with Prader-Willi. But UF researchers found that starting treatments can worsen or trigger sleep apnea in obese children exposed to colds, potentially leading to death, according to findings published online recently in The Journal of Clinical Endocrinology and Metabolism.

"Every kid we studied had abnormal sleep at the beginning, before growth hormone," said Jennifer Miller, M.D., a UF assistant professor of pediatrics and the study's lead author. "On growth hormone, most of them got better but not all of them. The ones that got worse tended to be school age. Some of them were just entering school and then they were coming home with upper-respiratory infections.

"The combination of starting growth hormone, still having weak muscle tone, having an illness and/or being obese tends to put you at risk for having really bad obstructive sleep apnea."

The researchers urge doctors to monitor patients' sleep before and during treatment for signs of obstructive sleep apnea, such as loud snoring or abnormal daytime sleepiness. Sleep studies are recommended for all obese children, not just those with Prader-Willi, Miller added.

Prader-Willi syndrome is caused by a rare chromosomal defect and occurs in only one of every 12,000 to 15,000 people, according to the Pra
'"/>

Contact: April Frawley Birdwell
afrawley@vpha.health.ufl.edu
352-273-5817
University of Florida
18-Jan-2006


Page: 1 2 3

Related biology news :

1. Growth factors and environment combine to increase brain maturation
2. Growth factor signals influence balance between normal growth and cancerous growth
3. Growth factor triggers growth of new blood vessels in the heart
4. Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons
5. Growth hormone is made in the brain, report scientists
6. Growth in biomass could put US on road to energy independence
7. Growth disorder gene plays a big role in normal size variation
8. Growth factor in baby formula could reduce NEC, most devastating GI disease in preemies
9. Growth in the sea comes down to a struggle for iron
10. Growth of common skin cancer blocked in gene-switch mice
11. Growth factors confer immortality to sperm-generating stem cells

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Growth hormone obesity can trigger sleep apnea some kids

(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: